Pegbelfermin - Bristol-Myers Squibb
Alternative Names: ARX-618; BMS 986036; FGF-21 mimetic proteins; PEG-FGF21; Pegbelfermin; Pegylated FGF21; Pegylated-fibroblast growth factor-21Latest Information Update: 13 Mar 2024
At a glance
- Originator Ambrx
- Developer Bristol-Myers Squibb
- Class Antifibrotics; Antihyperglycaemics; Fibroblast growth factors; Hepatoprotectants; Obesity therapies; Polyethylene glycols; Proteins
- Mechanism of Action Fibroblast growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fibrosis; Liver disorders; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
- 10 Nov 2023 Efficacy data from a phase II trial in Nonalcoholic Steatohepatitis resented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 02 Jun 2022 Bristol-Myers Squibb completes a phase I trial in Liver disorders (In Adults) in USA (NCT04634149)